News 06 Dic 2023 Advance Capital expands its footprint in Switzerland with the opening of a new subsidiary in Geneva Advance Capital, the French financial expert, opens a subsidiary in Geneva, strengthening its presence and offering direct access to the Swiss ma...
Actualités 06 Dic 2023 Advance Capital étend son empreinte en Suisse avec l’implantation d’une nouvelle filiale à Genève Advance Capital, expert français en finance, ouvre une filiale à Genève, renforçant sa présence et offrant un accès direct au marché suisse.
ニュース 02 Giu 2023 欧州のバイオテクノロジー企業の20%がスイスに本社を置いていることが判明 Press release IQVIAが実施し、このほど発表された「2023スイスバイオテックレポート」によると、欧州のバイオテクノロジー企業の20%がスイスに本社を置いていることが明らかになりました。さらに、スイス連邦政府、州、地域による投資促進に関する昨年の統計でも、この傾向が続いていることが確認されています。
Aktuell 02 Giu 2023 Neuste Forschung zeigt, dass 20% der europäischen Biotechs ihren Hauptsitz in der Schweiz haben Press release Neue Untersuchungen von IQVIA, die kürzlich im Swiss Biotech Report 2023 veröffentlicht wurden, zeigen, dass mittlerweile 20% der europäischen Bi...
News 24 Ago 2023 Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking Drawing from the achievements of its parent company, Nanobacterie, Valais-based AlphaOnco Swiss stands at the forefront of innovative nanomedicin...
最新 02 Giu 2023 最新研究显示,目前有20%的欧洲生物科技公司将总部设在瑞士 Press release 由 IQVIA 进行的新研究和最近发布的《2023瑞士生物科技报告》显示,目前有20%的欧洲生物科技公司将总部设在瑞士。此外,瑞士联邦政府、各州和地区去年的投资促进统计数据证实,这一趋势仍在继续。
뉴스 02 Giu 2023 최신 연구에 따르면 유럽 바이오테크 기업의 20%가 스위스에 본사를 두고 있습니다 Press release IQVIA가 수행하고 최근 2023 스위스 바이오테크 보고서에 발표된 새로운 연구에 따르면 유럽 바이오테크 기업의 20%가 현재 스위스에 본사를 두고 있습니다. 또한 스위스 연방 정부, 주 및 지역의 작년 투자 유치 통계에 따르면 이러한 추세가 지속되고 있음을...
Aktuell 24 Gen 2023 Verve Ventures ist unter den aktivsten Investoren Europas Die Risikokapitalfirma Verve Ventures wird von Sifted, dem europäischen Start-up-Medium der „Financial Times", zu den aktivsten in Europa gezählt...
Actualités 24 Ago 2023 Le pionnier de la nanomédecine Nanobacterie se distingue par ses brevets Forte des réalisations de sa société mère Nanobacterie, la société valaisanne AlphaOnco Swiss est à l'avant-garde des traitements anticancéreux i...
News 24 Mag 2023 Latest research shows 20% of European biotechs now headquartered in Switzerland Press release New research conducted by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20% of European biotech companies are now head...
Actualités 02 Giu 2023 UNE ÉTUDE RÉCENTE MONTRE QUE 20 % DES SOCIÉTÉS DE BIOTECHNOLOGIE EUROPÉENNES ONT DÉSORMAIS LEUR SIÈGE EN SUISSE Press release Une nouvelle étude menée par IQVIA et récemment publiée dans le Swiss Biotech Report 2023 montre que 20 % des sociétés de biotechnologie eur...
Spotlight 15 Giu 2023 Access to Ecosystem Switzerland is a global leader in biotech, medtech and pharma. Find out what makes the Swiss life science industry unique and how your life scien...
Novità 02 Giu 2023 Le ultime ricerche indicano che il 20% delle aziende biotecnologiche europee ha attualmente sede in Svizzera Press release Una nuova ricerca condotta da IQVIA e pubblicata recentemente nello Swiss Biotech Report 2023 mostra che il 20% delle aziende biotecnologiche eur...
News 24 Gen 2023 Verve Ventures among the most dynamic investors in Europe The venture capital firm Verve Ventures has been recognized as one of the most active investors in Europe by Sifted, the European start-up medium...
Global Opportunities 27 Giu 2022 Mailand verwandelt ehemaliges Expo-Gelände in grosses Innovationsviertel Nur etwa 40 km von der Schweizer Grenze entfernt, bietet das neue Innovationsviertel ein einzigartiges Umfeld für Schweizer Unternehmen, die bere...
Expertise 07 Giu 2022 Digital Cleantech Solutions for Construction and Finance As we move deeper into the decade and adjust to the realities of the evolving pandemic, the race to meet decarbonization and emissions reductions...
Global Opportunities 20 Giu 2022 Milano transforms Expo area in major Innovation District Just some 40km from the Swiss border, the new pole offers a unique ecosystem for Swiss companies who are already active in Italy or monitoring up...
News 20 Lug 2022 Forty51 closes first fund totaling 43 million US dollars A new Basel-based venture fund, Forty51 Ventures I, has raised a total of 43 million US dollars following a first fund closing. Forty51 invests i...